2026 Abstract Awards
Congratulations to the PSMA & Beyond 2026 Abstract Award Winners!
- Albert Jang (Mayo Clinic) - PSMA+ extracellular vesicles (EVs) and circulating tumor DNA (ctDNA) reveal potential biomarkers of response to 177Lu-PSMA-617
Melissa Abel (National Cancer Institute) - Evolution of local prostate/prostate bed PSMA findings in PSMA+ Biochemically Recurrent Prostate Cancer
Karam Masri (UCLA) - Differences in Absorbed Dose Estimates from Commercially Available Software
Poster Abstracts at the 2026 PSMA & Beyond Conference
| Abstract # | First Author / Presenter | Affiliation | Title of Abstract |
| 1 | Andrea Di Giorgio Presented by: Riccardo Mei | University of Bologna, Italy | PSMA PET/CT–Targeted Biopsy in Men with Negative or Equivocal mpMRI and Dynamic Total-Body PET Kinetic Analysis: A Prospective Single-Centre Study |
| 2 | Koichiro Kimura | UCLA | Detection Rate of Prostate Cancer Using Prostate-Specific Membrane Antigen/Ultrasound-Fusion Biopsy in Patients with Suspected Recurrence or Inconclusive/Negative Biopsies: A Single-Center Retrospective Study |
| 3 | Clint Bahler Presented by: Wayne Brisbane | Indiana University UCLA Study sponsored by Telix Pharmaceuticals | Phase 3 study of 68Ga-PSMA-11 PET combined with MRI for the detection of prostate cancer (BIPASS) |
| 4 | Zahra Mohammadigoldar | UCLA | Role of PSMA PET/CT and mpMRI in determining focal therapy eligibility in localized prostate cancer: correlation with histopathology |
| 5 | Jiyoun Seo | Cedars- Sinai Medical Center | Multi-omic Characterization of Imaging-Invisible Prostate Tumors Reveals Microenvironmental Drivers of PET Visibility |
| 6 | Caner Civan Presented by: Wolfgang Fendler | University Hospital Essen, Germany | New Prostate Cancer Risk Groups by PSMA-PET (PPP3) |
| 7 | Ramotallah Jubril | Purdue University, Indianapolis, IN | Linking Clinicopathologic Factors and PSMA-PET Detection to Recurrence Pattern and Salvage Radiotherapy Outcomes |
| 8 | Bashirul Azam Biswas | Dartmouth, Hanover, NH | Uncertainty- and tracer-aware multi-tracer, pan-cancer lesion segmentation on PET/CT images |
| 9 | Benjamin Osborn | Perceptive Imaging | AI Enabled Lesion Analysis in PSMA-PET: Comprehensive Lesion Segmentation, Delineation, and Classification |
| 10 | Abuzar Moradi Tuchayi | UCSF | PSMA PROGRESS: a longitudinal database to understand the impact of changes seen on PSMA PET |
| 11 | Melissa Abel | National Cancer Institute | Evolution of local prostate/prostate bed PSMA findings in PSMA+ Biochemically Recurrent Prostate Cancer |
| 12 | Chae Moon Hong | UCSF | Comparative analysis of treatment response to radioligand therapy using Ga-68 PSMA-11 and F-18 DCFPyL PET Imaging |
| 13 | Biratal Raj Wagle | Dartmouth, Hanover, NH | Automated identification of prostate cancer patients with high-risk bone metastasis eligible for radiation therapy from whole-body PSMA-PET/CT scans |
| 14 | Grant Chau | Dartmouth, Hanover, NH | Improving Metastasis Detection on PSMA-PET with Whole-Body Atlases and Deep Learning |
| 15 | Kevin Walsh | UCLA | Diagnostic Performance of an AI Prostate Cancer Mapping Tool Versus PSMA PET-CT and MRI |
| 16 | Marcus Steward | Siemens Medical Solutions USA | Performance evaluation of an AI PET/CT whole-body lesion segmentation software in advanced prostate cancer |
| 17 | Harish Nagaraj | Kenyatta University Teaching Referral and Research Hospital (KUTRRH), Nairobi, Kenya | First-ever Lutetium-177 PSMA Radioligand Therapy Delivered at a Public Referral Hospital in Kenya: A Milestone for Regional Access to Theranostic Care. |
| 18 | Farzana Ali | UCLA | Impact of Bone-Directed Radiation Therapy on Radium-223 Response in mCRPC: A Retrospective Analysis Correlated with PSMA PET/CT and Bone Scan |
| 19 | Miguel Muniz | Mayo Clinic, Rochester, MN | SPPADE symptom burden and ePRO-based outcome prediction in patients with mCRPC treated with 177Lu-PSMA-617 (LuPSMA) |
| 20 | Laura Aussage Presented by: Jonathan Vigne | CHU Caen Normandie, France | Global pharmacovigilance insights into [¹⁷⁷Lu]Lu-PSMA-617: a disproportionality-based safety signal detection approach using VigiBase |
| 21 | Zachary Scharf | Mayo Clinic, Rochester, MN | An Assessment of Time Toxicity in Patients Receiving [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
| 22 | Benjamin Fongenie | Blue Earth Therapeutics | Estimating the impact of 212Bi demetallation from administration of 212Pb-rhPSMA-10.1 and the risk of significant Kidney Absorbed Radiation Doses |
| 23 | Albert Jang | Mayo Clinic, Rochester, MN | PSMA+ extracellular vesicles (EVs) and circulating tumor DNA (ctDNA) reveal potential biomarkers of response to 177Lu-PSMA-617 |
| 24 | Jack Andrews Presented by: Fabrice Lucien | Mayo Clinic, Scottsdale, AZ Mayo Clinic, Rochester, MN | PSMA+ Tumor Derived Extracellular Vesicles are a Blood-Based Biomarker for risk stratification and response to SABR in Oligorecurrent Prostate Cancer: Post-hoc analysis of the ORIOLE, STOMP-like and RAVENS cohorts |
| 25 | Riccardo Mei | Azienda Ospedaliero-Universitaria di Bologna, Italy | Understanding Lesion Response to Treatment Using Dynamic PSMA PET in Patients with Metastatic Prostate Cancer: Preliminary Results from the PELICAN Study |
| 26 | Katelyn Niknam | VA Greater Los Angeles | Prospective study to evaluate usefulness of Fluciclovine F 18 in predicting clinical outcome in patients undergoing radioligand therapy with 177Lu-PSMA-617 |
| 27 | Giorgia Ricciardello | University of Messina, Italy | The predictive role of SPECT/CT semiquantitative parameters at the first RLT cycle with [177Lu]Lu-PSMA-617 in advanced mCRPC: a preliminary lesion-based analysis |
| 28 | Zachary Ells | UCLA | Do increased injected activities exceeding 7.4 GBq [177Lu]Lu-PSMA-I&T lead to increased absorbed doses to tumors and kidneys? |
| 29 | Zachary Ells Presented by: Karam Masri | UCLA | Differences in Absorbed Dose Estimates from Commercially Available Software |
| 30 | Thomas Hope | UCSF | Pharmacokinetics and dosimetry of Lutetium Lu 177 zadavotide guraxetan in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the ECLIPSE sub-study |
| 31 | Loïc Djaileb | Université Grenoble Alpes, UCLA | PSMA uptake differences between [68Ga]-Ga-PSMA-11 PET and [177Lu]-PSMA SPECT in metastatic castration resistant prostate cancer patients treated with 177Lu]-PSMA-617 therapy: post-hoc analysis from the Prospective Multicenter Phase 2 Trial RESIST-PC |
| 32 | Loïc Djaileb Presented by: Andrei Gafita | Université Grenoble Alpes, UCLA Johns Hopkins University, Baltimore, Maryland | Clinical Impact of Changes in Tumor Uptake and Volume on PSMA-PET/CT during [177Lu]Lu-PSMA in Metastatic Castration-Resistant Prostate Cancer |
| 33 | Iveta Fajnorova | UCLA | Integrating PSCA-CAR-T Cell Therapy with PSMA-Targeted Radioligands (177Lu vs 225Ac) for Advanced Prostate Cancer |
| 34 | Min Hong Presented by: Guangzhou Han | RadAlliance Therapeutics | First-in-Human Evaluation of ⁶⁴Cu-RAX301: A Novel High-Affinity PSMA PET Tracer for Enhanced Detection of Metastatic Prostate Cancer |
| 35 | Adrien Holzgreve | UCLA | Randomized phase 2 trial of flexible and extended dosing of 177Lu-PSMA-617 molecular radioligand therapy (FLEX-MRT): 2025 Study Protocol Update |
| 36 | Thomas Hope | UCSF | Radioligand Efficacy Comparison By Initial PSA-Response Outcome in Metastatic HRPC with Lutetium (RECIPROCAL): A phase 3 randomized trial (A032304) |
| 37 | Malick Bio Idrissou | University of Wisconsin–Madison | Next-Generation PSMA Therapy: [¹⁶¹Tb]Tb-ART-101 achieves superior tumor absorbed dose and anti-tumor efficacy in advanced prostate cancer |
| 38 | Adrien Holzgreve | UCLA | Correlation of [68Ga]Ga-FAPI-46 PET and FAP immunohistochemistry in a case series of the prospective exploratory trial NCT04147494 |
| 39 | Aviral Singh Presented by: Aaron Enke | GenesisCare Murdoch Hospital, Perth; Australia 3B Pharmaceuticals | Therapeutic Potential of the Novel PSMA-Binding Peptide NTA-476 Demonstrated in Several Clinical Studies |
| 40 | Suchismita Mohanty Presented by: Aaron Cooper | ArsenalBio | Preclinical development of AB-3028, a programmable circuit PSMA-targeting CAR T cell product intended for the treatment of metastatic castration-resistant prostate cancer (mCRPC) |
For questions, please contact [email protected].